Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GRLSbn | Madrid | EUR | Delayed | |
GRLS | Derived | EUR | Real-time | |
GRLS | Madrid | EUR | Delayed | |
GRFPe | BATS Europe | EUR | Delayed | |
GRFe | BATS Europe | EUR | Delayed | |
GIKLY | OTC Markets | USD | Delayed | |
GRFS | NASDAQ | USD | Real-time | |
0RDU | London | EUR | Real-time | |
0RDV | London | EUR | Real-time | |
GRFPN | Mexico | MXN | Delayed | |
GRLS | Vienna | EUR | Real-time |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Name | Age | Since | Title |
---|---|---|---|
Darcy Antonellis | 61 | 2023 | Non-Executive Director |
Tomas Daga Gelabert | 68 | 2000 | Independent External Director |
Enriqueta Felip Font | 60 | 2019 | Independent Director |
Albert Grifols Coma-Cros | 46 | 2023 | Proprietary Director |
Susana Gonzalez Rodriguez | 48 | 2022 | Independent Director |
Montserrat Muñoz Abellana | 56 | 2022 | Lead Independent Director |
Anne-Catherine Berner | - | 2024 | Independent Director |
Iñigo Sánchez-Asiaín Mardones | 60 | 2015 | Independent Director |
Víctor Grifols Deu | 47 | 2016 | Executive Director |
Jose Ignacio Abia Buenache | 56 | 2024 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review